NEWS & RELEASES

News and information about DAMIAN and Primary Aldosteronism. 

At DAMIAN, we’re about passion, not convenience.

Teresa Gerlock
Chief Operating Officer
  • DAMIAN receives research grant from Innosuisse

    Innosuisse awards third Swiss research grant to DAMIAN to support the further development of its new research project DP20. The new funding supports a collaboration between DAMIAN and its three research partners: Fachhochschule Nordwest Schweiz, ETH Zurich and the University of Bern.

  • DAMIAN announces dexfadrostat phosphate achieves high efficacy in PA patients

    DAMIAN announces new data from the Phase II trial in patients with primary aldosteronism (PA), that showed the investigational compound dexfadrostat phosphate effectively reduced both aldosterone-to-renin ratio (ARR) and ambulatory systolic blood pressure (aSBP). The trial met both primary endpoints with high significance.  

    https://dampha.s3.us-east-2.amazonaws.com/assets/uploads/damian-press-release-phase-2-data.pdf

  • DAMIAN successfully completes Phase II study of dexfadrostat phosphate (DP13)

    DAMIAN completed the first Phase II study of an aldosterone synthase inhibitor in patients with primary aldosteronism using its novel compound, dexfadrostat phosphate (DP13), in May 2022.  

  • DAMIAN clinical plan affirmed by the Foundation for Therapeutic Research

    The Lausanne-based Foundation for Therapeutic Research awards a grant for the development of new therapeutic principles in cardiovascular disease to the University of Torino to investigate dexfadrostat phosphate (DP13). The grant supports the Phase I clinical trial of dexfadrostat phosphate, the first-in-class aldosterone synthase inhibitor from DAMIAN.

  • DAMIAN conducts Phase I study of dexfadrostat phosphate (DP13) 

    DAMIAN executes its Phase I proof-of-concept, double-blind, safety and tolerability study of dexfadrostat phosphate in healthy volunteers (NCT03046589). The Phase I study successfully completed in September 2018.

  • DAMIAN initiates Phase II study of dexfadrostat phosphate (DP13) 

    DAMIAN enrolls the first patients in its multinational Phase II study of dexfadrostat phosphate in patients with Primary Aldosteronism (NCT04007406; EUDRACT# 2019-000919-85).

  • DAMIAN receives research grant from Innosuisse (formerly CTI)

    Innosuisse awards second Swiss research grant to DAMIAN to support the further development of its diagnostic tool, DP14. The new funding follows the successful completion of the design phase and allows the team to execute the in vivo proof-of-concept experiments.